GlassScriptPhysician profile
Abbas Rattani
NPI 1700346368
$1,803.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $1,494 · 2022: $138.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $395.91 | 2020-2022 | |
| Coherus Oncology, INC. | $342.53 | 2021 | |
| Eisai INC. | $220.75 | 2021 | |
| Incyte Corporation | $158.64 | 2020-2021 | |
| Tersera Therapeutics LLC | $125.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Boston Scientific Corporation | $123.42 | 2021 | |
| Celgene Corporation | $88.04 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $87.68 | 2021 | |
| Merck Sharp & Dohme LLC | $86.74 | 2020-2022 | |
| Ambu INC. | $21.35 | 2021 | |
| Amgen INC. | $15.50 | 2020 | |
| Genzyme Corporation | $12.94 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Rattani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.